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Introduction
When a mammography screening program is fully 
implemented, interval cancers comprise a substantial 
proportion of incident breast cancers. Interval cancers 
could have been overlooked at the previous mammography 
examination or become apparent because they grew 
rapidly such that the detectable preclinical phase was 
shorter than that of the screening interval. In Korea, 
the incidence rate of interval breast cancers (ICs) per 
100,000 negative findings increased from 51.7 in 2009 
to 76.3 in 2014 (Lee et al., 2016). Although research on 
interval cancer of mammography screening has focused 
on survival comparing to different groups. Several studies 
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(Collett et al.,2005; Bellio et al., 2005; Sihto et al., 2008) 
have reported that the prognosis of ICs considered is 
poorer than that of screening-detected breast cancers 
because IC tumors are, on average, larger than those of 
more advanced cancers, and tried to identify women at 
risk of ICs. Previous randomized trials on mammography 
screening found that ICs were associated with similar 
(Holmberg et al., 1986; Delacour-Billon et al., 2017), 
better (Frisell et al., 1992) or poorer (Andersson et al., 
1998; Musolino  et al., 2018) survival compared to that 
of non-screened breast cancers. Kalager et al., (2012) 
reported in an observational cohort study that the prognosis 
of women with ICs was the same as that of women with 
breast cancer diagnosed without mammography screening. 
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They concluded that IC tumors are more likely to be larger 
than those of non-screening-detected cancers, but have 
similar survival outcomes and provided no compelling 
support for more aggressive primary treatment of ICs than 
non-screening-detected cancers.
The National Health Insurance Service (NHIS) 
in Korea began screening for breast cancer using 
mammography once every two years without copayment 
in 1999, targeting women with medical aid who were 
over 40 years of age. An increasing tendency in screening 
rate in Korea was observed before 2012 (70.2%), which 
decreased from 2012 to 2014 (59.3%) in all age groups 
(Suh et al., 2016). These decreasing rates may be due to 
negative press messages about mammography screening 
in Korea since 2012. In addition, the limitations of 
screening mammography include a painful procedure, 
high false-positive rates, and misdiagnosis, especially for 
ICs in younger women (Lee et al., 2016; Kim and Kim, 
2016; Suh et al., 2016). Therefore, this study evaluated 
patients who have ever breast cancer screening before a 
diagnosis of breast cancer for determining the frequency 
of reported ICs, associated reproductive or social factors, 
short term-clinical outcomes and for highlighting the risk 
of ICs from a cancer registry database.
Materials and Methods
Study cohort
The KBCR is a prospectively maintained, web-based 
database of the Korean Breast Cancer Society (Moon et 
al., 2009; Moon et al., 2010). The registry is estimated 
to include more than 65% of all newly diagnosed breast 
cancer patients in Korea in 2013 (Min et al., 2016). 
Between January 2009 and December 2013, a total of 
63,381 patients were enrolled by 102 general hospitals, 
including 41 university hospitals and 61 surgical training 
hospitals. Patients with male sex, previous history of breast 
cancer, or treatment with neoadjuvant chemotherapy were 
excluded. The history of screening by mammography was 
unknown in almost half of these cases; after excluding these 
cases, a total of 27,143 (42.8%) patients were included in 
the final analysis. Cancer that occurs within 12 months 
after negative results on cancer screening are defined 
interval cancer and we classified 27,143 patients by status 
of interval breast cancer (Figure 1). Personal interviews 
were conducted with each patient at the time of diagnosis 
to generate information about each subject, including 
demographic information, reproductive variables (age 
at menarche, menopause, pregnancy, childbirth, and age 
at first birth [AFB]). The database provided information 
about sex, age, type of operation, stage according to 6th 
American Joint Committee on Cancer classification, 
histological findings and the presence of biological 
markers, adjuvant therapy, and status of interval cancer 
was reported by physicians. Status of survival and cause 
of death until 31, Dec, 2014, which was obtained from the 
Ministry of Health and Welfare, Republic of Korea. The 
mean duration of follow-up was 40.17 months (±17.48, 
11.9-72.73). This study was approved by the Institutional 
Review Board (IRB number: HPIRB 2017-07-639-001) 
and was conducted in accordance with the Declaration 
of Helsinki.
Statistical analysis 
The clinicopathologic characteristics of ICs and 
non-ICs were compared using Х2 and t-tests. Multivariate 
Cox proportional hazard models were used to determine 
the effect of interval breast cancer on disease-free survival 
(DFS) (or death due to breast cancer) and overall survival 
(OS) (deaths from any cause) rates as dependent variables 
and adjusting for age and stage. Hazard ratios (HR) and 
95% confidence intervals (CI)s were calculated for the 
following study factors: age at diagnosis (<35, 35-44, 
45-54, ≥55); menarche (<13, 13-15, ≥16); tumor size 
(≤1cm, 1.1-2.0cm, ≥2.1cm); number of child (0-1, 2-3, 
≥4); educational level ( high school, elementary, college, 
none, middle school); family history ( no, yes), and 
hormone replacement therapy( never, ever). We identify 
all statistical methods and verified the assumptions for 
all statistical tests which are performed by two-sided. All 
analyses were performed using SAS (Version 9.4, SAS, 
Inc., Cary, NC). Alpha for all statistical tests was 0.05. 
Statistical significance was assumed for p < 0.05.
Results
Characteristics of IC in KBCR data
The proportion of ICs was 1.36 % (370/27,143). The 
proportion of ICs was correlated with age between 45 and 
55 years at diagnosis, between 25 and 34 years at first 
birth, and family history of breast cancer. In menopausal 
patients with breast cancers, early menopause (<50 
years) and use of hormonal replacement therapy were 
correlated with the proportion of ICs. The proportion of 
ICs was also significantly higher in patients with higher 
levels of education (Table 1) and in specific provinces 
(Kyung-nam, Dae-jeon, Jeju, Kang-won) (Figure 2). 
Marriage status, breastfeeding, use of oral contraceptives, 
age at menarche, parity, symptomatic disease, and body 
mass index (BMI) were not correlated with ICs. Regarding 
tumor characteristics, ICs were also correlated with low-
to-intermediate nuclear grade, early stage (stage 0-I), 
negative Her-2/neu expression, and low Ki-67 levels. 
However, tumor size did not differ significantly between 
the two groups. The operation methods also differed, with 
breast-conserving surgery and sentinel lymph node biopsy 
highly correlated with ICs (Table 2). 
DFS and associated factors in patients with breast cancer 
with mammography screening
Patients with breast cancer who had never received 
adjuvant endocrine therapy or asymptomatic women 
showed highest HR of five-year DFS. Conversely, age at 
diagnosis (45-55) had a decreased HR of five-year DFS 
(HR 0.13; 95% CI:0.05-0.35; p <0.001) compared those 
of the other age groups. Women who entered menarche 
at 13-15 years of age showed a decreased HR of five-
year DFS (HR 0.16; 95%CI: 0.06-0.42; p = 0.0002) 
compared to that in the other age groups. Compared 
to high parity (≥4), parity (≤3) had a decreased HR of 
five-year DFS. The educational level also affected the 
prognosis. A high educational level (above high school) 
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Non IC (Case/ %) IC (Case/ %) Total p-valuea
Age at diagnosis <35 1,181 (4.45) 9 (2.51) 1,190 (4.3) <0.006
35≤ <45 6,646 (25.05) 85 (23.74) 6,731 (24.8)
45≤ <55 10,545 (39.74) 178 (49.72) 10,723 (39.5)
≥55 8,164 (30.77) 86 (24.02) 8,250 (31.4)
BMI( Kg/m2) <18.5 1,534 (5.78) 25 (6.98) 1,559 (5.7) 0.735
18.5-24.9 17,462 (65.8) 235 (65.64) 17,697 (64.5)
25-29.9 6,403 (24.13) 83 (23.18) 6,486 (23.9)
30-34.9 1,005 (3.79) 12 (3.35) 1,017 (3.7)
≥35 132 (0.5) 3 (0.84) 135 (0.5)
Menarche <13 5,791 (21.82) 68 (18.99) 5,859 (21.6) 0.106
13-15 14,001 (52.76) 209 (58.38) 14,210 (52.3)
≥16 6,744 (25.41) 81 (22.63) 6,825 (25.1)
Menopause <50 20,677 (77.92) 288 (80.45) 20,965 (77.2) 0.006
50-54 4,847 (18.27) 68 (18.09) 4,915 (17.9)
≥55 1,012 (3.81) 2 (0.56) 1,014 (3.7)
Number of child 0-1 8,159 (61.78) 85 (63.91) 8,244 (61.8) 0.07
2-3 3,546 (26.85) 41 (30.83) 3,587 (26.9)
≥4 1,502 (11.37) 7 (5.26) 1,509 (11.3)
Age at first birth ≤24 12,040 (45.37) 140 (39.11) 12,180 (45.3) 0.024
25-34 13,754 (51.83) 211 (58.94) 13,965 (51.9)
≥35 742 (2.8) 7 (1.96) 749 (2.8)
Education level High school 9,077 (39.78) 117 (36.79) 9,194 (39.7) 0.02
Elementary 2,607 (11.43) 26 (8.18) 2,633 (11.4)
College 7,778 (34.09) 133 (41.82) 7,911 (34.2)
None 507 (2.22) 3 (0.94) 510 (2.2)
Middle school 2,847 (12.48) 39 (12.26) 2,886 (12.5)
Marriage status No 1,864 (7.21) 19 (5.38) 1,883 (7.2) 0.18
Yes 23,978 (92.79) 334 (94.62) 24,312 (92.8)
Breast feeding No 7,408 (31.44) 96 (28.15) 7,504 (31.4) 0.19
Yes 16,154 (68.56) 245 (71.85) 16,399 (68.6)
Oral Contraceptive No 21,449 (88.7) 290 (86.8) 21,739 (88.5) 0.27
Yes 2,725 (11.3) 44 (13.2) 2,769 (21.5)
HRT No 22,619 (91.04) 287 (85.42) 22,906 (90.9) 0.0004
Yes 2,227 (8.96) 49 (14.58) 2,276 (9.1)
Family history No 23,688 (90.56) 300 (87.21) 23,988 (90.5) 0.03
Yes 2,469 (9.44) 44 (12.79) 2,513 (9.5)
Symptom No 18,597 (70.08) 203 (56.7) 18,800 (69.9) <0.001
Yes 7,939 (29.92) 155 (43.3) 8,094 (30.1)
Table 1. Comparison of Social Characteristics between Non-IBC and IBC among Patients with Breast Cancers Who 
Attended Ever Breast Cancer Screening
BMI, Body Mass Index; HRT; Hormonal Replacement Therapy; IC, Interval Cancer; ap values were calculated using the Х2 and t-tests.
was associated with a decreased HR of the five-years 
DFS (HR 0.13; 95%CI:0.02-0.69; p = 0.01) compared 
to that of other educational levels. Negative lymph node 
metastasis showed a relatively good prognosis compared 
to that of positive lymph node metastasis (HR 0.12; 95% 
CI:0.05-0.30; p <0.001). The other clinical factors and 
residence did not show prognostic effects on the five-year 
DFS (Table 3). Because of the short follow-up period and 
low frequency of deaths, we could not perform a stratified 
analysis between the IC and non-IC groups.
OS and associated factors in patients with breast cancer 
with mammography screening 
Compared to ICs, non-ICs increased the HR of a 
five-year OS (HR 7.4; 95%CI: 1.85-29.66; p = 0.005)
(Figure 3). Residence (Kyung-nam province), low 
education status (non-educated or elementary school), 
high histologic grade, asymptomatic cancers, and patients 
without adjuvant endocrine therapy had an increased HR 
of five-year OS. Age at diagnosis (35-44 years) or (45-54 
years) decreased the HR of five-year OS (HR 0.55; 95%CI: 
Jung Sun Lee et al
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Non IC (Case/ %) IC (Case/ %) Total p-valueb
Tumor size ≤1cm 7695 (29) 108 (30.17) 7,803 (29.0) 0.24
1-2cm 9,352 (35.24) 137 (38.27) 9,489 (35.3)
>2cm 9,489 (35.76) 113 (34.56) 9,602 (35.7)
Stage 0 3,319 (12.51) 53 (14.8) 3,372 (13.0)) <0.001
I 11,069 (41.43) 174 (47.03) 1,1243 (43.4)
II 8,558 (31.9) 98 (26.5) 8,656 (33.4)
III 2,331 (8.7) 26 (7.0) 2,357 (9.1)
IV 281 (1.06) 2 (0.5) 283 (1.1)
Operation_breast BCS 16,880 (64.02) 255 (71.23) 17,135 (64.1) 0.03
MRM 9,342 (35.43) 101 (28.21) 9,443 (35.3)
Operation_axilla ALND 4,108 (15.51) 43 (12.01) 4,151 (15.5) 0.012
SLNB 1,578 (57.31) 236 (65.92) 15,414 (57.4)
SLNB+ALND 5,066 (19.13) 54 (15.08) 5,120 (19.1)
None 2,130 (8.04) 25 (6.98) 2,155 (8.0)
ER Negative 7,246 (28.53) 96 (27.35) 7,342 (28.7) 0.22
Positive 17,959 (70.72) 255 (72.65) 18,214 (71.3)
PR Negative 9,958 (39.27) 148 (42.17) 10,106 (39.6) 0.16
Positive 15,209 (59.98) 203 (57.83) 15,412 (60.4)
HER2overexpession Negative 18,443 (69.5) 272 (75.98) 18,715 (80.1) <0.001
Positive 5,566 (20.98) 78 (21.79) 5,644 (19.9)
Ki-67 low 2,695 (13.53) 41 (23.43) 2,736 (13.6) <0.001
high 17,228 (86.47) 134 (76.57) 17,362 (86.4)
Chemotherapy No 9,919 (40.19) 165 (47.41) 10,084 (40.3) 0.006
Yes 14,759 (59.81) 183 (52.59) 14,942 (59.7)
Radiotherapy No 7,117 (29.61) 75 (21.37) 7,192 (29.5) 0.001
Yes 16,915 (70.39) 276 (78.63) 17,191 (70.5)
Endocrine therapy No 7,339 (31.68) 96 (27.59) 7,435 (31.7) 0.1
Yes 15,829 (68.32) 252 (72.41) 16,081 (68.3)
Table 2. Comparison of Tumor Characteristics between Non-IBC and IBC
ER, Estrogen Receptor; PR, Progesterone Receptor, HER-2; Human Epidermal Receptor-2/ neu; IC, Interval Cancer; bp values were calculated 
using the Х2 and t-tests.
Figure 1. Flow Chart Representing the Selection Procedure Based on the KBCR Dataset from 2009-2013
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0.44-0.68; p <0.001), (HR 0.52; 95%CI: 0.43-0.63; p 
<0.001). Women who entered menarche at 13-15 years 
of age decreased HR of five-year OS (HR 0.70; 95%CI: 
0.58-0.83; p <0.0001). Compared with high parity (≥4), 
any parity (≤ 3) including nulliparous women, decreased 
HR of five-year OS. Negative lymph node metastasis 
HR 95% CI p-valuec
Age at diagnosis <35
35≤ <45
45≤ <55 0.136 0.05 0.35 <0.001
≥55 1 ref
Menarche <13 0.585 0.24 1.4 0.22
13-15 0.16 0.06 0.42 0.0002
≥16 1 ref
Tumor size ≤1cm 0.96 0.44 2.09 0.92
1.1-2.0 cm 0.35 0.13 0.98 0.04
≥2.1 cm 1 ref
Number of child 0-1 0.15 0.062 0.409 0.0001
2-3 0.2 0.072 0.599 0.003
≥4 1 ref
Education level High school 0.13 0.02 0.69 0.01
Elementary 2.35 0.81 6.77 0.11
College 0.18 0.03 0.93 0.04
None 0.94 0.11 8.06 0.95
Middle school 1 ref
HRT No 1.22 0.28 5.19 0.78
Yes 1 ref
Family history No 2.49 0.34 18.34 0.36
Yes 1 ref
Symptom No 3..21 1.12 9.19 0.03
Yes 1 ref
LN metastasis No 0.12 0.05 0.3 <0.001
Yes 1 ref
Endocrine therapy No 6.55 2.4 17.88 0.0002
Yes 1 ref
Table 3. HRs with Corresponding 95% CI s of Tumor Characteristics in 5-Years Disease Free Survival
HRT, Hormonal Replacement Therapy; HR, Hazard Ratio; CI, Confidence Interval; LN, Lymph Node; cp values were calculated using the Х2 and 
t-tests.
Figure 2. Regional Distribution of Interval Breast Cancer in Korea (2009-2013)
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HR 95% CI p-valued
Age at diagnosis <35 0.78 0.55 1.12 0.19
35≤ <45 0.55 0.44 0.68 <0.001
45≤ <55 0.52 0.43 0.63 <0.001
≥55 1 ref
Menarche <13 0.99 0.8 1.23 0.96
13-15 0.7 0.58 0.83 0.0001
≥16 1 ref
Tumor size ≤1cm 0.36 0.29 0.045 <0.0001
1.1-2.0cm 0.32 0.26 0.39 <0.0001
≥2.1cm 1 ref
Number of child 0-1 0.7 0.53 0.92 0.012
2-3 0.56 0.41 0.77 0.0004
≥4 1 ref
Education level High school 0.95 0.72 1.25 0.74
Elementary 1.58 1.17 2.15 0.003
College 0.77 0.58 1.04 0.09
None 2.2 1.43 3.38 0.0003
Middle school 1 ref
HRT No 1.17 0.87 1.57 0.28
Yes 1 ref
Family history No 1.03 0.78 1.38 0.79
Yes 1 ref
Symptom No 2.69 2.16 3.35 <0.0001
Yes 1 ref
Province Kangwon 1.47 0.7 3.05 0.3
Kyung-gi 1.24 0.7 2.2 0.44
Kyung-nam 1.94 0.02 3.69 0.04
Kyung-buk 1.18 0.58 2.41 0.64
Gwang-ju 0.68 0.28 1.65 0.4
Dae-gu 1.82 0.92 3.59 0.08
Dae-jeon 0.92 0.43 1.93 0.83
Busan 1 0.52 1.93 0.97
Seoul 1.43 0.81 2.52 0.21
Ulsan 1.76 0.93 3.35 0.08
Incheon 1.65 0.88 3.08 0.11
Jeo-nam 1.3 0.63 2.65 0.46
Jeon-buk 1.74 0.94 3.23 0.07
Jeju 1.11 0.31 3.91 0.86
Chung-nam 1.31 0.67 2.56 0.42
Chung-buk 1 ref
LN metastasis No 0.29 0.24 0.34 <0.001
Yes 1 ref
HG G1 0.78 0.23 2.57 0.68
G2 1.39 0.44 4.38 0.56
G3 4.33 1.39 13.52 0.011
LVI No 0.31 0.26 0.36 <0.001
Yes 1 ref
Ki-67 No 0.21 0.13 0.34 <0.001
Yes 1 ref
Table 4. HRs with Corresponding 95% CI s of Tumor in 5-Years Overall Survival
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showed a relatively good prognosis compared to that 
of positive lymph node metastasis (HR 0.29; 95%CI: 
0.24-0.34; p <0.001). Other known prognostic factors 
(Ki-67, lymphovascular invasion, Her-2/neu, and tumor 
size) showed a negative correlation with the five-year 
OS (Table 4).
Discussion
The cancer screening rate in this study (42.8%) was 
lower than that reported in a National Breast Cancer 
Screening Project report (59.3%) (Suh et al., 2016). Even 
though of enrollment younger than 40 years women in the 
cancer registry, it could be a considerable low screening 
rate. This finding reflects trends in decreasing screening 
rates. Korean women may prefer to check their breast by 
ultrasonography because personal invitation letter after 
the screening was inconclusive, disbelief of the findings, 
or discomfort regarding screening mammography (Kim 
et al., 2017). 
We observed a very lower proportion of ICs (1.3%) 
from registry data in the same period. About the incidence 
of ICs in Korea, it has been reported that it increased from 
5.2 persons in 2009 to 7.8 persons per 10,000 negative 
mammography findings in 2014 (Lee et al., 2016), similar 
to those reported in other countries (Kemp Jacobsen et 
al., 2015). But direct comparison with this study was not 
appropriate because this study was from a large-scale 
observational study of Korean NHISS, it did not use actual 
biannual screening interval, but current study was from 
registry data, used actual screening interval (2 years). 
Actual incidence rate of ICs need to re-analyze with 
an actual screening interval from Korean breast cancer 
screening program. We started it through big data sharing 
program from Korean NHISS. 
We observed significant correlations between ICs 
among women with a family history of breast cancer. 
In concordance with this, Holm et al., (2015) reported 
a two-fold increase in the odds for ICs among BRCA 
mutation carriers, in line with our results. Other studies 
of BRCA mutations have reported a lowered sensitivity 
of mammography screening for carriers (Brekelmans et 
al., 2001; Komenaka et al., 2004). However, previous 
literature (Domingo et al., 2010; Kirsh et al., 2011; 
HR 95% CI p-valued
HER2 overexpression Negative 0.26 0.16 0.43 <0.001
Positive 1 ref
Radiotherapy No 1.16 0.97 1.39 0.08
Yes 1 ref
Chemotherapy No 0.47 0.39 0.58 <0.001
Yes 1 ref
Endocrine therapy No 3.28 2.75 3.93 <0.001
Yes 1 ref
IC No 1 ref <0.004
Yes 7.41 1.85 29.66
Table 4. Continued
HRT, Hormonal Replacement Therapy; HR, Hazard Ratio; CI, Confidence Interval; LN, Lymph node; HG, Histologic Grade; LVI, Lymphvascular 
invasion; HER-2; Human Epidermal Receptor-2/neu; IC, Interval Cancer dp values were calculated using the Х2 and t-tests.
Figure 3. Kaplan- Meier Curve of 5 Years Overall- Survival
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Musolino et al., 2012; Blanch et al., 2014) on family 
history and ICs reports conflicting results, using varying 
definitions of family history and low patient numbers. 
We observed a small effect of family history on interval 
cancer, but results require confirmation in larger studies. 
In particular, educational level is an important 
health determinant and is an important predictor of 
participation in certain types of cancer screening. In a 
meta-analysis, Damiani et al., (2012) reported a positive 
association between education level and adherence to 
breast cancer screening. Other studies (Damiani et al., 
2012; Martín-López et al.,2012) observed that women 
with a lower level of education tended to adhere more to 
organized screening programs than to opportunistic ones. 
Educational level was a strong independent prognostic 
factor in other Korean breast cancer studies and Hwang et 
al., (2017) reported that a high education level conferred a 
superior prognosis compared to that of a low educational 
level which was consistent with this study. High educated 
women were frequently diagnosed as ICs, but the 
prognosis of them was better. Many factors could be 
related to this correlation at both at contextual level, such 
as the type of health care provider, the accessibility to care, 
and at the individual level such as age, location, income, 
private insurance coverage status, and occupational status.
The distribution of tumor characteristics between ICs 
and non-ICs overall was not in full agreement with other 
literature, with ICs being larger at diagnosis (Komenaka 
et al., 2004; Brekelmans et al., 2001), of higher grade 
(Domingo et al., 2010; Kirsh et al., 2011; Meshkat et al., 
2015), and displaying more lymph node involvement 
(Musolino et al., 2012; Blanch et al., 2014) and more often 
being ER/PR-negative (Damiani et al., 2015; Musolino 
et al., 2018), HER2-positive (Martín-López et al., 2012; 
Musolino et al., 2018), or triple negative (Gilliland et 
al., 2000). As results, these studies have reported that IC 
tumors had, on average, a poorer prognosis of ICs than 
those of screening-detected breast cancers (Andersson et 
al., 1998; Collett et al., 2005; Sihto et al., 2008). While 5 
years overall survival of ICs is better than non- ICs who 
have ever participated in breast screening in the current 
study, in addition to favorable features. To highlight the 
cause of differences in molecular characteristics of IC 
compared to other studies, large-scaled prospective studies 
or a centralized tumor bank are needed. Previous studies 
have reported differences in molecular characteristics 
between ICs and screening-detected breast cancers. Rojo 
et al., (2014) showed differential expression profiles both 
at gene and protein levels, especially mTOR signaling, 
which is upregulated in true interval cancers, suggesting 
that this pathway may mediate aggressiveness. Li et 
al., (2015) first reported that these two types of breast 
cancer may have unique underlying biology based on a 
77 single-nucleotide polymorphism risk score However, 
a recent, well-designed study indicated molecular 
differences between less aggressive screening-detected 
breast cancer and more aggressive ICs. The two diseases 
are biologically distinct in terms of somatic mutations, 
copy number aberrations, and gene expression, but most of 
these differences are no longer significant after adjusting 
for breast cancer subtypes and mammography density 
(Li et al., 2017).
Province was concerned as associated factors for 
OS. Specific location (Kyung-nam province) need 
improvement in prognosis which could conceivably be 
attained through increased public education and awareness 
of interval breast cancer. In 2012, Disparities on cancer 
screening or cancer survival were reported, consistent with 
present study (Khang and Lee, 2012). Based on actual 
short term survival rather than actual short term DFS, 
the present results are likely to be due to socio-economic 
factors such as income and educational level rather than 
treatment differences for breast cancer. In order to reduce 
this disparity, various institutional and non-institutional 
devices need to be prepared and operated in Korea.
This study has several limitations. First, the study 
assessed several associated host factors including age, 
family history, hormone replacement therapy, residence, 
and educational level, but it did not assess their independent 
contributions. Second, because of short follow-up and low 
mortality rate, we could not perform a stratified analysis 
between the IC and non-IC groups. Third, the proportion 
of IC from registry dataset was relatively lower than that 
reported in other studies (Kalager et al., 2012; Bellio 
et al., 2017; Delacour-Billon et al., 2017; Musolino et 
al., 2018) or in the health insurance claim data (Lee et 
al., 2016). The reason is that the source of data is not 
from a national cancer screening dataset but a cancer 
registry that includes 81.1 % of all incident breast cancers 
(Oh et al., 2016). The registry is based on voluntarily 
participating breast surgeons of teaching hospitals in 
Korea. Thus a considerable number of study participants 
with missing values can be expected and selection bias 
is possible. This data also depend on diagnosis of ICs 
by physicians, and unpredictable under- diagnosis may 
happen. However, many studies have reported high 
correlations between the rates derived from chart audits 
and patient surveys (Montano et al., 1995; Hoffmeister et 
al., 2007). Nevertheless, this study has several strengths 
compared to the national breast cancer screening 
database. First, data from physician or patient interviews 
have more definitive categorization than those of other 
retrospective observational studies because these data 
excluded end-stage breast cancer patients who received 
only palliative treatment with no anti-cancer treatment or 
surgery. Second, the present study included more social 
and environmental factors to assess their relationship with 
ICs in Korea. Because of rapid increasing breast cancer 
risk factors in Korea, such as having lower child-birth 
(if any) at an older age and high educational level, these 
related factors could play role on the occurrence of ICs 
as limitation of screening. 
In conclusion, among women with breast cancer who 
have ever undergone breast screening, ICs and non-ICs 
showed disparate clinicopathologic features and regional 
or educational disparities. While the mammography-based 
screening has been helpful for the early detection of breast 
cancer, detection of ICs is a limitation with decreased 
examinee compliance. Nevertheless, the proportion of IC 
was very low in KBCR and the short-term survival was 
significantly better than non-ICs. 
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